My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 721

    1.

    The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.

    Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ.

    Diabetes. 2002 Jan;51(1):189-97.PMID: 11756340 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.

    Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ.

    Blood. 2000 Aug 1;96(3):988-95.PMID: 10910914 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.

    Greenberg CS, Miraglia CC, Rickles FR, Shuman MA.

    J Clin Invest. 1985 May;75(5):1463-70.PMID: 2860124 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit.

    Bagoly Z, Fazakas F, Komáromi I, Haramura G, Tóth E, Muszbek L.

    Thromb Haemost. 2008 Apr;99(4):668-74.PMID: 18392324 [PubMed - indexed for MEDLINE]Related articles

    5.

    Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.

    Siebenlist KR, Meh DA, Mosesson MW.

    Thromb Haemost. 2001 Nov;86(5):1221-8.PMID: 11816711 [PubMed - indexed for MEDLINE]Related articles

    6.

    The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma.

    Shemirani AH, Haramura G, Bagoly Z, Muszbek L.

    Biochim Biophys Acta. 2006 Aug;1764(8):1420-3. Epub 2006 Jul 12.PMID: 16920044 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A.

    Lee IH, Chung SI, Lee SY.

    Exp Mol Med. 2002 Nov 30;34(5):385-90.PMID: 12526104 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.

    Greenberg CS, Achyuthan KE, Rajagopalan S, Pizzo SV.

    Arch Biochem Biophys. 1988 Apr;262(1):142-8.PMID: 2895608 [PubMed - indexed for MEDLINE]Related articles

    9.

    Probing interactions between the coagulants thrombin, Factor XIII, and fibrin(ogen).

    Maurer MC, Trumbo TA, Isetti G, Turner BT Jr.

    Arch Biochem Biophys. 2006 Jan 1;445(1):36-45. Epub 2005 Dec 1.PMID: 16364233 [PubMed - indexed for MEDLINE]Related articles

    10.

    FXIII polymorphisms, fibrin clot structure and thrombotic risk.

    Kobbervig C, Williams E.

    Biophys Chem. 2004 Dec 20;112(2-3):223-8.PMID: 15572253 [PubMed - indexed for MEDLINE]Related articles

    11.

    The role of gamma A/gamma ' fibrinogen in plasma factor XIII activation.

    Moaddel M, Falls LA, Farrell DH.

    J Biol Chem. 2000 Oct 13;275(41):32135-40.PMID: 10913112 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function.

    Muszbek L, Adány R, Mikkola H.

    Crit Rev Clin Lab Sci. 1996 Oct;33(5):357-421. Review.PMID: 8922891 [PubMed - indexed for MEDLINE]Related articles

    13.

    The influence of type 2 diabetes on fibrin structure and function.

    Dunn EJ, Ariëns RA, Grant PJ.

    Diabetologia. 2005 Jun;48(6):1198-206. Epub 2005 Apr 29.PMID: 15864538 [PubMed - indexed for MEDLINE]Related articles

    14.

    Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure.

    Cooper AV, Standeven KF, Ariëns RA.

    Blood. 2003 Jul 15;102(2):535-40. Epub 2003 Mar 27.PMID: 12663453 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects.

    Undas A, Brzezinska-Kolarz B, Brummel-Ziedins K, Musial J, Szczeklik A, Mann KG.

    J Thromb Haemost. 2005 Sep;3(9):2015-21.PMID: 16102108 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Inhibition of factor XIII activation by an anti-peptide monoclonal antibody.

    Lukacova D, Matsueda GR, Haber E, Reed GL.

    Biochemistry. 1991 Oct 22;30(42):10164-70.PMID: 1681898 [PubMed - indexed for MEDLINE]Related articles

    17.

    Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras.

    Hettasch JM, Peoples KA, Greenberg CS.

    J Biol Chem. 1997 Oct 3;272(40):25149-56.PMID: 9312126 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerization mechanism.

    Mullin JL, Gorkun OV, Lord ST.

    Biochemistry. 2000 Aug 15;39(32):9843-9.PMID: 10933802 [PubMed - indexed for MEDLINE]Related articles

    19.

    Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation. Competition for cofactor sites on thrombin determines its fate.

    Philippou H, Rance J, Myles T, Hall SW, Ariens RA, Grant PJ, Leung L, Lane DA.

    J Biol Chem. 2003 Aug 22;278(34):32020-6. Epub 2003 Jun 6.PMID: 12794066 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    The effect of fibrin polymers on thrombin-catalyzed plasma factor XIIIa formation.

    Greenberg CS, Miraglia CC.

    Blood. 1985 Aug;66(2):466-9.PMID: 2861869 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity